首页> 外文期刊>Heartdrug: excellence in cardiovascular trials >Polymorphisms in the Apolipoprotein(a) Gene, Plasma Lp(a) and Cardiovascular Risk
【24h】

Polymorphisms in the Apolipoprotein(a) Gene, Plasma Lp(a) and Cardiovascular Risk

机译:载脂蛋白(A)基因,血浆LP(A)和心血管风险中的多态性

获取原文
获取原文并翻译 | 示例
           

摘要

Increased plasma concentration of lipoprotein(a) [Lp(a)] represents an established risk factor for coronary artery disease (CAD). The plasma Lp(a) level is relatively stable during life and it is more than 90% genetically determined by the apolipoprotein(a) [apo(a)] gene. Numerous polymorphisms have been identified in the apo(a) gene. The extreme apo(a) protein size polymorphism, based on the variable number of so-called kringle IV type 2 repeats (KIV-2), accounts for a large portion of variability of plasma Lp(a) levels. Moreover, it has been shown that several other apo(a) sequence changes, both in the coding and regulatory sequences, influence plasma Lp(a) levels and/or Lp(a) prothrombogenic properties.ssociations between some of them and the increased risk of CAD have also been reported. However, the existence of strong linkage disequilibria in the apo(a) locus represents a serious problem to identify a real effect of single polymorphism on Lp(a) phenotype. Large and complex association and family studies in different populations, together with in vitro expression and functional studies, should clarify the importance of so far identified positive apo(a) polymorphism-plasma Lp(a) associations in the future. In addition, standardization of measurement of Lp(a) is necessary to allow comparison of results obtained with different immunoassays.
机译:脂蛋白的血浆浓度升高(A)[LP(A)]代表冠状动脉疾病(CAD)的既定危险因素。血浆LP(a)水平在生命中相对稳定,由载脂蛋白(A)[Apo(a)]基因确定了90%以上的遗传确定。在APO(a)基因中已经鉴定出许多多态性。极端的APO(A)蛋白质大小多态性基于所谓的Kringle IV类型2重复序列(KIV-2)的可变数量,占血浆LP(a)水平可变性的很大一部分。此外,已经表明,在编码和调节序列中,其他几个APO(a)序列都会改变等离子LP(a)水平和/或LP(a)促进性特性。也已经报道了CAD。但是,Apo(a)基因座中强链的存在不平衡是一个严重的问题,即确定单个多态性对LP(a)表型的实际影响。在不同人群中的大而复杂的关联和家庭研究,以及体外表达和功能研究,应阐明迄今为止确定的阳性APO(a)多态性血压LP(a)将来的关联。另外,必须进行LP(a)测量的标准化,以比较与不同的免疫测定结果获得的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号